Cantitate/Preț
Produs

Indacaterol: The First Once-daily Long-acting Beta2 Agonist for COPD: Milestones in Drug Therapy

Editat de Alexandre Trifilieff
en Limba Engleză Hardback – 27 noi 2013
Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
Citește tot Restrânge

Din seria Milestones in Drug Therapy

Preț: 67761 lei

Preț vechi: 71328 lei
-5% Nou

Puncte Express: 1016

Preț estimativ în valută:
12970 13946$ 10813£

Carte tipărită la comandă

Livrare economică 19 decembrie 24 - 02 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783034807081
ISBN-10: 3034807082
Pagini: 156
Ilustrații: VII, 146 p. 41 illus., 21 illus. in color.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.41 kg
Ediția:2014
Editura: Springer
Colecția Springer
Seria Milestones in Drug Therapy

Locul publicării:Basel, Switzerland

Public țintă

Research

Cuprins

Current Pharmacotherapy for COPD.- The preclinical pharmacology of indacaterol.- The design of the indacaterol molecule.- The early clinical development of Indacaterol.- INHANCE: An adaptive confirmatory study with dose selection at interim.- Phase III clinical efficacy studies – lung function.- Phase III Clinical Efficacy of Indacaterol.- Patient-centered Outcomes.- The history and performance of the Breezhaler device.- What does the future hold for the therapy of COPD?  

Textul de pe ultima copertă

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.
This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

Caracteristici

Summarizes preclinical and clinical data A valuable source of information for scientists and clinicians Contemporary monograph on the pharmacotherapy of COPD Includes supplementary material: sn.pub/extras